GAP-134

Modify Date: 2024-01-10 12:10:12

GAP-134 structure	Common Name	GAP-134
	CAS Number	943134-39-2	Molecular Weight	291.30200
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₄H₁₇N₃O₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of GAP-134

Danegaptide (GAP-134), a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.

Name	(2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid
Synonym	More Synonyms

Description	Danegaptide (GAP-134), a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.
Related Catalog	Signaling Pathways >> Cytoskeleton >> Gap Junction Protein Research Areas >> Cardiovascular Disease
Target	Gap junction.
In Vitro	Gap junction uncoupling can alter conduction pathways and promote cardiac re-entry mechanisms that potentiate many supraventricular arrhythmias, such as atrial fibrillation (AF) and atrial flutter (AFL). Gap junction modifier Danegaptide (GAP-134), showed consistent efficacy on measures of conduction and AF/AFL inducibility in the canine sterile pericarditis model. Danegaptide (GAP-134) is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, as already confirmed in phase I clinical trials.
References	[1]. De Vuyst E, Boengler K, Antoons G, et al. Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. Br J Pharmacol. 2011 Jun;163(3):469-83. [2]. Laurent G, Leong-Poi H, Mangat I, et al. Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs. Circ Arrhythm Electrophysiol. 2009 Apr;2(2):171-8. [3]. Hennan JK, Swillo RE, Morgan GA, et al. GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Cardiovasc Pharmacol Ther. 2009 Sep;14(3):207-14. [4]. Rossman EI, Liu K, Morgan GA, et al. The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33. [5]. Eugene L. Piatnitski Cheklera, John A. Buterab, Li Dib, Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents. Bioorganic & Medicinal Chemistry Letters. 2009,19(16): 4551-4554

Molecular Formula	C₁₄H₁₇N₃O₄
Molecular Weight	291.30200
Exact Mass	291.12200
PSA	116.22000
LogP	0.64220
Storage condition	2-8℃

(2S,4R)-4-Benza...

CAS#:943134-34-7

GAP-134

CAS#:943134-39-2

Literature: Bioorganic and Medicinal Chemistry Letters, , vol. 19, # 16 p. 4551 - 4554

Boc-Gly-OH

CAS#:4530-20-5

benzoic acid

CAS#:65-85-0

N-Boc-trans-4-N...

CAS#:176486-63-8

GAP-134

CAS#:943134-39-2

Literature: US2007/149460 A1, ; Page/Page column 33-34 ; US 20070149460 A1

Precursor 4
CAS#:943134-34-7 (2S,4R)-4-Benza... CAS#:4530-20-5 Boc-Gly-OH CAS#:65-85-0 benzoic acid CAS#:176486-63-8 N-Boc-trans-4-N...
DownStream 0

zp1609

danegaptide

gap-134

unii-pa0y7735at

GAP-134

Use of GAP-134

Names

GAP-134 Biological Activity

Chemical & Physical Properties

Synthetic Route

Precursor & DownStream

Synonyms